Drug Type Antibody fusion proteins |
Synonyms- |
Target |
Action inhibitors |
Mechanism CTLA4 inhibitors(Cytotoxic T-Lymphocyte-Associated Antigen 4 inhibitors), TIGIT inhibitors(T cell immunoglobulin and ITIM domains inhibitors) |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Diabetes Mellitus, Type 1 | Preclinical | China | 06 Jun 2024 | |
| Rheumatoid Arthritis | Preclinical | China | 06 Jun 2024 |






